评估取代的 6-芳基喹唑啉-4-胺作为有效的和选择性的细胞分裂周期蛋白 2 样激酶（Clk）抑制剂。
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
机构信息
NIH Chemical Genomics Center, National Human Genome Research Institute, Bethesda, MD 20892-3370, USA.
出版信息
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6700-5. doi: 10.1016/j.bmcl.2009.09.121. Epub 2009 Oct 3.
Abstract
A series of substituted 6-arylquinazolin-4-amines were prepared and analyzed as inhibitors of Clk4. Synthesis, structure-activity relationships and the selectivity of a potent analogue against a panel of 402 kinases are presented. Inhibition of Clk4 by these agents at varied concentrations of assay substrates (ATP and receptor peptide) highly suggests that this chemotype is an ATP competitive inhibitor. Molecular docking provides further evidence that inhibition is the result of binding at the kinase hinge region. Selected compounds represent novel tools capable of potent and selective inhibition of Clk1, Clk4, and Dyrk1A.
摘要
一系列取代的 6-芳基喹唑啉-4-胺被制备并分析为 Clk4 的抑制剂。本文介绍了合成、构效关系以及针对 402 种激酶的一个有效类似物的选择性。这些试剂在不同浓度的测定底物（ATP 和受体肽）下对 Clk4 的抑制强烈表明该化学型是一种 ATP 竞争性抑制剂。分子对接进一步提供了抑制是由于结合在激酶铰链区域的证据。选定的化合物代表了能够有效且选择性抑制 Clk1、Clk4 和 Dyrk1A 的新型工具。
相似文献
1
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).评估取代的 6-芳基喹唑啉-4-胺作为有效的和选择性的细胞分裂周期蛋白 2 样激酶（Clk）抑制剂。
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6700-5. doi: 10.1016/j.bmcl.2009.09.121. Epub 2009 Oct 3.
2
Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.作为细胞分裂周期蛋白依赖性激酶 4（Clk4）和双特异性酪氨酸磷酸化调节激酶 1A（Dyrk1A）抑制剂的 6-芳基喹唑啉-4-胺的药效团和 3D-QSAR 特征描述。
J Chem Inf Model. 2013 Apr 22;53(4):938-47. doi: 10.1021/ci300625c. Epub 2013 Apr 4.
3
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).强效且选择性的 Cdc2 样蛋白激酶（Clk）和双重特异性酪氨酸磷酸化调节激酶（Dyrk）的特定同工型的小分子抑制剂。
Bioorg Med Chem Lett. 2011 May 15;21(10):3152-8. doi: 10.1016/j.bmcl.2011.02.114. Epub 2011 Mar 4.
4
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.新型吡啶并[3,4-g]喹唑啉衍生物作为 CLK1 和 DYRK1A 的抑制剂：合成、生物评价及结合模式分析。
Eur J Med Chem. 2019 Mar 15;166:304-317. doi: 10.1016/j.ejmech.2019.01.052. Epub 2019 Jan 26.
5
Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.发现 DB18，一种强效的 CLK 激酶抑制剂，对 DYRK1A 激酶具有很高的选择性。
Bioorg Med Chem. 2021 Feb 1;31:115962. doi: 10.1016/j.bmc.2020.115962. Epub 2020 Dec 31.
6
Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.作为选择性双重特异性酪氨酸激酶/细胞周期蛋白依赖性激酶（Dyrk/Clk）抑制剂的类先导物2,4-双杂环取代噻吩库的设计与合成。
PLoS One. 2014 Mar 27;9(3):e87851. doi: 10.1371/journal.pone.0087851. eCollection 2014.
7
Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.4-苯胺基喹唑啉衍生物作为蛋白激酶抑制剂的合成、生物学评价及分子模拟研究
Bioorg Med Chem. 2014 Mar 15;22(6):1909-15. doi: 10.1016/j.bmc.2014.01.044. Epub 2014 Jan 31.
8
Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.发现吡啶并[3,4-g]喹唑啉衍生物作为 CMGC 家族蛋白激酶抑制剂：设计、合成、抑制活性和 X 射线共晶结构。
Eur J Med Chem. 2016 Aug 8;118:170-7. doi: 10.1016/j.ejmech.2016.04.004. Epub 2016 Apr 5.
9
Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.cdc2 样激酶与新型抑制剂化学型复合物的分子结构。
PLoS One. 2018 May 3;13(5):e0196761. doi: 10.1371/journal.pone.0196761. eCollection 2018.
10
Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.人类类周期蛋白依赖性激酶1（CLK1）：阿尔茨海默病的新靶点。
Curr Drug Targets. 2014 May;15(5):539-50. doi: 10.2174/1389450115666140226112321.
引用本文的文献
1
Global transcriptome modulation by xenobiotics: the role of alternative splicing in adaptive responses to chemical exposures.外源性化合物对全球转录组的调节：可变剪接在化学暴露适应反应中的作用。
Hum Genomics. 2024 Nov 18;18(1):127. doi: 10.1186/s40246-024-00694-6.
2
Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning.新型细胞周期蛋白依赖性激酶2样激酶4（CLK4）抑制剂的发现——结合基于柔性对接的配体/受体接触指纹图谱和机器学习的药效团探索
RSC Adv. 2022 Apr 5;12(17):10686-10700. doi: 10.1039/d2ra00136e. eCollection 2022 Mar 31.
3
Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.基于功能基因组的体内果蝇模型系统，合理设计并鉴定受去氢骆驼蓬碱启发的新型 N-杂环 DYRK1A 抑制剂。
ChemMedChem. 2022 Feb 16;17(4):e202100512. doi: 10.1002/cmdc.202100512. Epub 2022 Jan 27.
4
Design and Microwave Synthesis of New (5) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5) 2-Amino-5-arylidene-1,3-thiazol-4(5)-one as New Inhibitors of Protein Kinase DYRK1A.新型（5）5-亚芳基-2-硫代-1,3-噻唑烷-4-酮和（5）2-氨基-5-亚芳基-1,3-噻唑-4（5）-酮作为蛋白激酶DYRK1A新型抑制剂的设计与微波合成
Pharmaceuticals (Basel). 2021 Oct 27;14(11):1086. doi: 10.3390/ph14111086.
5
5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.5-甲氧基苯并噻吩-2-甲酰胺类化合物作为 Clk1/4 的抑制剂：选择性和细胞效力的优化。
Molecules. 2021 Feb 13;26(4):1001. doi: 10.3390/molecules26041001.
6
Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.CDC 样激酶（CLKs）：生物学、化学探针和治疗潜力。
Int J Mol Sci. 2020 Oct 13;21(20):7549. doi: 10.3390/ijms21207549.
7
Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.cdc2 样激酶与新型抑制剂化学型复合物的分子结构。
PLoS One. 2018 May 3;13(5):e0196761. doi: 10.1371/journal.pone.0196761. eCollection 2018.
8
CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.新型小分子抑制剂揭示了CLK依赖性外显子识别与连体基因形成。
Nat Commun. 2017 Feb 23;8(1):7. doi: 10.1038/s41467-016-0008-7.
9
Pharmacology of Modulators of Alternative Splicing.可变剪接调节剂的药理学
Pharmacol Rev. 2017 Jan;69(1):63-79. doi: 10.1124/pr.115.011239.
10
A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.一种经证实具有临床安全性的化学物质通过抑制DYRK1A挽救唐氏综合征相关表型。
Dis Model Mech. 2016 Aug 1;9(8):839-48. doi: 10.1242/dmm.025668. Epub 2016 Jul 7.
本文引用的文献
1
QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.作为双重特异性酪氨酸磷酸酶样激酶1A（Dyrk1A）抑制剂的吡唑烷-3,5-二酮衍生物的定量构效关系（QSAR）分析
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2324-8. doi: 10.1016/j.bmcl.2009.02.062. Epub 2009 Feb 21.
2
Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.Akt2对类Cdc2激酶（Clk/Sty）的调控、丝氨酸/精氨酸丰富（SR）蛋白的磷酸化以及胰岛素诱导的蛋白激酶CβII信使核糖核酸的可变剪接
Endocrinology. 2009 May;150(5):2087-97. doi: 10.1210/en.2008-0818. Epub 2008 Dec 30.
3
A quantitative analysis of kinase inhibitor selectivity.激酶抑制剂选择性的定量分析。
Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358.
4
DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.DYRK1A介导的Tau蛋白过度磷酸化。唐氏综合征与阿尔茨海默病之间的功能联系。
J Biol Chem. 2007 Nov 30;282(48):34850-7. doi: 10.1074/jbc.M707358200. Epub 2007 Sep 28.
5
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.唐氏综合征患者大脑中由三体性驱动的DYRK1A激酶过表达。
Neurosci Lett. 2007 Feb 8;413(1):77-81. doi: 10.1016/j.neulet.2006.11.026. Epub 2006 Dec 4.
6
Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets.组织因子前体信使核糖核酸的信号依赖性剪接调节人类血小板的血栓形成能力。
J Exp Med. 2006 Oct 30;203(11):2433-40. doi: 10.1084/jem.20061302. Epub 2006 Oct 23.
7
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.索拉非尼的发现与研发：一种用于治疗癌症的多激酶抑制剂
Nat Rev Drug Discov. 2006 Oct;5(10):835-44. doi: 10.1038/nrd2130.
8
Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.定量高通量筛选：一种基于滴定的方法，可有效识别大型化学文库中的生物活性。
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11473-8. doi: 10.1073/pnas.0604348103. Epub 2006 Jul 24.
9
Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.用于唐氏综合征患者学习和记忆缺陷的潜在治疗药物。
Bioorg Med Chem Lett. 2006 Jul 15;16(14):3772-6. doi: 10.1016/j.bmcl.2006.04.042. Epub 2006 May 12.
10
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.DYRK1A细菌人工染色体转基因小鼠表现出突触可塑性改变，并伴有学习和记忆缺陷。
Neurobiol Dis. 2006 Jun;22(3):463-72. doi: 10.1016/j.nbd.2005.12.006. Epub 2006 Feb 7.
Zotero 插件